Pulmonary fibrosis

Pulmonary fibrosis, also known as interstitial lung disease, is a group of conditions characterized by progressive changes in lung tissue leading to its replacement with fibrous tissue. This process disrupts the normal structure of the lungs and their functionality, which in turn leads to deterioration of gas exchange. Clinically, it manifests itself as progressive dyspnea, cough, and decreased physical endurance. Fibrosis can be a consequence of various factors, including chronic inflammation, autoimmune diseases, and exposure to harmful substances. Understanding the mechanisms of pathogenesis and risk factors for this disease is important for its early diagnosis and adequate treatment.

History of the disease and interesting historical facts

Pulmonary fibrosis has been mentioned in medical texts since ancient times. One of the first documented cases is the work of Hippocrates, in which he described the condition of the lungs of patients with chronic dyspnea. Over the centuries, medical research has greatly expanded our understanding of the mechanisms and causes of this disease. In the 20th century, especially after World War II, pulmonary fibrosis became the subject of research programs related to the effects of chemicals and asbestos on human health. In the 1980s, intensive study of the immunological aspects of fibrosis began, leading to the designation of its various forms, such as idiopathic pulmonary fibrosis. Importantly, with the development of imaging technologies such as computed tomography, the diagnosis of pulmonary fibrosis has become more accurate and accessible.

Epidemiology

The epidemiology of pulmonary fibrosis varies by region, occupation, and environmental factors. According to various studies, the prevalence of idiopathic pulmonary fibrosis is about 3-12 cases per 100,000 people, with men being more susceptible to this disease than women. According to studies, the incidence of the disease increases with age, reaching a maximum at the age of over 65 years. It is also noted that the disease is more common among people working in hazardous conditions, such as in industries with high levels of dust, asbestos, or other toxic substances. Data on the pediatric population show extremely rare cases of pulmonary fibrosis, which emphasizes its predominant development in the adult population.

Genetic predisposition to this disease

Research suggests that genetic predisposition may play a role in the pathogenesis of pulmonary fibrosis. Several genes associated with inflammation and lung tissue remodeling have been identified as potential risk factors. For example, an association has been found between idiopathic pulmonary fibrosis and polymorphisms in the TERT, TERC, and MUC5B genes. These mutations affect cellular proliferation and functionality of lung cells, which may lead to pathological changes in the interstitial tissue. Genetic studies continue to expand our understanding of the specific mutations and mechanisms that contribute to the development of this disease.

Risk factors for the development of this disease

Risk factors associated with the development of pulmonary fibrosis can be divided into physical and chemical. Physical factors include:

• Long-term exposure to dust, particularly silica and asbestos.
• Work in conditions of high humidity and dust.
• Occupational risks associated with industrial pollutants.

Chemical factors include:

• Exposure to toxic fumes and chemicals such as formaldehyde or isocyanates.
• Smoking, which also causes chronic pneumonia.
• Exposure to radiation.

There is also a link between autoimmune diseases and the development of fibrosis, which leads to the need for an integrated approach to assessing risk factors and pathogenesis.

Diagnosis of this disease

Diagnosis of pulmonary fibrosis involves several steps, starting with clinical evaluation and ending with complex laboratory and radiological studies. The main symptoms to look out for include:

• Progressive dyspnea.
• Dry cough.
• Fatigue and decreased physical activity.

Laboratory tests may include a complete blood count, pulmonary function tests, and biochemical analysis. Radiological tests, such as chest X-rays or CT scans, help visualize changes in lung tissue. Other diagnostic methods include bronchoscopy with lung tissue biopsy. Differential diagnosis of pulmonary fibrosis includes conditions such as pneumonia, lung cancer, tuberculosis, and pleurisy.

Treatment

Treatment for pulmonary fibrosis focuses on reducing symptoms and slowing the progression of the disease. It may include:

• General treatment aimed at maintaining lung function and improving quality of life.
• Pharmacological treatment, including the use of glucocorticosteroids and immunosuppressants to reduce inflammation.
• Surgical treatment, such as lung transplantation, is considered in severe cases.
• Other treatments include oxygen therapy and pulmonary rehabilitation.

It is important to emphasize that the approach to therapy should be individualized, taking into account the prognosis of the disease and the general condition of the patient.

List of medications used to treat this disease

Medicines used to treat pulmonary fibrosis include:

• Perfenidone.
• Nintedanib.
• Glucocorticosteroids (for example, prednisolone).
• Immunosuppressants (eg, azathioprine).
• Antioxidants and drugs to support lung function.

When choosing a therapy, it is important to consider not only the effectiveness of the drugs, but also their side effects and contraindications.

Disease monitoring

Monitoring a patient with pulmonary fibrosis involves regular assessments of lung function as well as clinical observation of symptoms. Monitoring steps may include:

• Periodic pulmonary function tests.
• Radiological examinations to assess disease progression.
• The patient's health status and the occurrence of complications such as lung infections.

The prognosis for pulmonary fibrosis varies, but in general the disease tends to progress, requiring close monitoring. Complications may include chronic respiratory failure and right-sided pain in patients with advanced disease.

Age-related features of the disease

Pulmonary fibrosis exhibits different patterns of progression depending on the patient’s age group. In younger people, the disease may progress more slowly and is more often associated with hereditary factors or external influences such as toxic substances. In older patients, the disease progresses more rapidly, which is associated with age-related changes in the lungs, comorbidities, and general physical predisposition. In addition, younger patients may tolerate therapy better, while older people often have difficulties due to comorbidities.

Questions and Answers

• What is pulmonary fibrosis? Pulmonary fibrosis is a disease in which lung tissue is replaced by fibrous tissue, leading to impaired gas exchange and progressive respiratory symptoms.
• What are the main causes of pulmonary fibrosis? The main causes of pulmonary fibrosis can be long-term exposure to chemicals, occupational hazards, autoimmune diseases and genetic predisposition.
• How is pulmonary fibrosis diagnosed? Diagnosis includes a thorough history, assessment of clinical symptoms, radiological and laboratory tests, including computed tomography and lung biopsy.
• Is it possible to treat pulmonary fibrosis? Treatment of pulmonary fibrosis is aimed at slowing the progression of the disease and improving the quality of life of patients and may include both drug and non-drug therapies.
• What is the prognosis for pulmonary fibrosis? The prognosis varies depending on the form of fibrosis, but in general the disease tends to progress, with potential for improvement with adequate therapy.